Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.
about
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept.Update on ranolazine in the management of angina.Emerging clinical role of ranolazine in the management of angina.Efficacy and safety of ranolazine in patients with chronic stable angina.Ranolazine: a review of its use in chronic stable angina pectoris.In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolitesRanolazine, a novel agent for chronic stable angina.Ranolazine: a new approach to management of patients with angina.Clinical pharmacokinetics of ranolazine.Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.Ranolazine: a new option in the management of chronic stable angina.A rare neurological complication of ranolazine.Pathophysiology of the cardiac late Na current and its potential as a drug target.Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.Efficacy of metabolic modulators in ischemic heart disease: an overview.Simvastatin interactions with other drugs.Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.Impact of pharmacists' interventions and simvastatin dose restrictions.Ranolazine for the treatment of atrial fibrillation.Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin.Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects.Effect of Multiple-Dose Diltiazem on the Pharmacokinetics of the Renin Inhibitor ACT-077825.Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models.Effect of botanical immunomodulators on human CYP3A4 inhibition: implications for concurrent use as adjuvants in cancer therapy.Clinical experience with ranolazine in a veteran population with chronic stable angina.Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin.Statin drug interactions and related adverse reactions: an update.Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model.Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?
P2860
Q24605881-5BAD55CA-0EAD-4967-835F-CAD94211EB93Q31140927-468FF038-798D-44AE-B2CA-2E7DF16EA3C2Q33831222-4525B2A4-155E-49DA-B89B-6962D30CAA5CQ34235939-86D67FE0-F9BF-43B0-A619-08656BBB1729Q34383219-BD86EFBA-3299-403E-9653-2D807A7F6542Q34566582-3AD6DF69-3E58-4153-82AE-1C99E84233D7Q36105348-BD45BFA0-9774-4EE7-B818-DB79AC6BC026Q36408751-D5E1DF48-8804-4D79-8A72-D636D259465FQ36440871-F3EDD97F-3190-4F2C-A896-919653DA8B6EQ36460838-CB97904B-1AB3-4598-817A-9EE355633C3BQ36935249-71AE48FE-55C8-4544-AE0F-4697BFE359DCQ37015957-92E870C9-FA47-4C32-A8E5-63A5DAB75454Q37018984-7026E504-340B-4BA1-96A0-38DB240AA947Q37276416-18AEB7FC-CED8-47B0-B0C4-5548E04311A3Q37495337-BEFEA959-4BBC-4711-8494-66827BF2096BQ37850633-69E6001A-31EF-4A6C-BEF3-1EF16C34FE8CQ37993600-DB94A4BB-4E0B-467D-87AB-8AB7AC19F4C1Q38074900-862A4A69-8F5B-4D56-8003-09DF3E39E6ADQ38164673-5AED70CD-9185-4EE6-A883-CA9FA0C01A54Q38420631-06E419DB-6A2B-4DBD-A834-C874D4DD395BQ38520990-9E7D64CC-969B-4824-ACEA-1A3537117124Q38707185-A705D3B9-F951-4022-9816-EC5DBB214078Q38819959-09E9AD3C-5954-460F-B2A1-6AD8661C97FFQ39472689-DCF5D722-1512-48FD-8F6B-B4282ABBB93DQ39816378-EE63E79A-F4CF-4844-BA8D-538FC4038C9CQ44451449-87B1CA27-66B6-4715-83F7-04C635BB412BQ45194833-ADE24247-0A7C-4506-9BB4-5CC8F4CA4565Q45330316-E387A2AF-2204-4794-BEFF-5DB4F40CD0F5Q46627530-6DAAE6B5-CF59-4837-9D8C-2B2D93CB3C0DQ48145497-FFA90A0A-EA79-4555-9B34-A3183DC2C4CCQ49140346-63C44D00-7E87-4A5C-B888-356321B66298Q51738040-F6CE7083-B5D6-41E3-9FB8-26A794AECAD0Q55080711-471EA036-FA39-40BC-BED8-EC88D7642A5B
P2860
Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Studies to investigate the pha ...... istration in healthy subjects.
@en
Studies to investigate the pha ...... istration in healthy subjects.
@nl
type
label
Studies to investigate the pha ...... istration in healthy subjects.
@en
Studies to investigate the pha ...... istration in healthy subjects.
@nl
prefLabel
Studies to investigate the pha ...... istration in healthy subjects.
@en
Studies to investigate the pha ...... istration in healthy subjects.
@nl
P2093
P2860
P356
P1476
Studies to investigate the pha ...... istration in healthy subjects.
@en
P2093
Bee-Lian Huan
Hisham Abdallah
Kwan Leung
Markus Jerling
Ziad Hussein
P2860
P304
P356
10.1177/0091270004273992
P577
2005-04-01T00:00:00Z